ASNC President Mouaz Al-Mallah, MD, and ASNC President-elect Larry Phillips, MD, discussed some of the key trends in cardiac molecular imaging at ACC.23.
Patients with pure native AR are often excluded from clinical trials comparing TAVR and SAVR, leading to a lack of clarity when it comes to the proper treatment of this population.
SCAI President Sunil Rao, MD, discussed the group's efforts to address the shift in interventional procedures from hospitals to less expensive ambulatory surgical centers.
An example of the FFR-CT technology from Heartflow. The vendor's AI can take a patient's cardiac CT scan and non-invasively assess FFR hemodynamic flow for all the coronary arteries to determine if blockages are significant enough to require revascularization.
The company is still riding the momentum of its technology being included in the 2021 American College of Cardiology/American Heart Association chest pain guidelines.
Abbott previously issued a voluntary medical device correction about this problem, but no recall had been announced at that time. The recall includes devices distributed from November 2017 to February 2023.
This new approach, which combines traditional intermittent fasting with 20-hour fasting periods on nonconsecutive days, could make a big impact on the cardiovascular health of high-risk patients.
According to an advisory on the FDA’s website, there is a “reasonable probability” that any immunocompromised patients exposed to the affected antibiotic could develop a life-threatening infection.
Eric Secemsky, MD, told Cardiovascular Business that a lack of training is one of the biggest factors limiting the use of intravascular imaging-guided PCI among interventional cardiologists.
